<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00920972</url>
  </required_header>
  <id_info>
    <org_study_id>201110144</org_study_id>
    <nct_id>NCT00920972</nct_id>
  </id_info>
  <brief_title>Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases</brief_title>
  <official_title>A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Non-Malignant Disease Using a Reduced-Intensity Preparatory Regime</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Louis Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis for this study is that a preparative regimen that maximizes host
      immunosuppression without myeloablation will be well tolerated and sufficient for engraftment
      of donor hematopoietic cells. It is also to determine major toxicities from these
      conditioning regimens, within the first 100 days after transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study uses reduced intensity conditioning that is immune suppressive to achieve donor
      cell engraftment without exposure to radiation or high dose chemotherapy in children with
      non-malignant disorders. The intent is to minimize early and late regimen related toxicities
      in the context of a reduced intensity regimen.

      In addition to maximizing opportunity for donor cell engraftment, the trial seeks to minimize
      toxicities associated with transplant such as graft versus host disease and employs GVHD
      prophylaxis that seeks to decrease rates of acute and chronic GVHD in the setting of matched
      and mismatched donor stem cell transplants from marrow and cord blood sources.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2001</start_date>
  <completion_date type="Anticipated">December 2031</completion_date>
  <primary_completion_date type="Anticipated">December 2026</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Donor engraftment as measured by chimerism</measure>
    <time_frame>100 days post-transplant</time_frame>
    <description>Engraftment is measured in myeloid and lymphoid lineage cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major toxicities as graded by the CTC v4</measure>
    <time_frame>100 days post-transplant</time_frame>
    <description>Toxicity monitoring includes unanticipated side effects (new) and all severe irreversible toxicities Grade 3 and above unexpected Grade 4 and above - all toxicities that are possibly, probably or definitely related to protocol therapy All deaths irrespective of attribution</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil and platelet engraftment as measured by complete blood counts</measure>
    <time_frame>Post transplant</time_frame>
    <description>Defined as an ANC &gt;500/microliter and platelets &gt;20,000 or 50,000/microliter depending on disorder</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute graft-versus-host disease as measured by protocol grading scale</measure>
    <time_frame>100 days post-transplant</time_frame>
    <description>aGVHD - involving the skin, gut and liver. Classified according to grading described by Thomas et al. NEJM 1975; 292:895-902</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic graft-versus-host disease as measured by protocol grading scale</measure>
    <time_frame>2 years post-transplant</time_frame>
    <description>cGVHD classified per Schulman et al. Am J Med 69: 204-17, 1980.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term donor engraftment by donor chimerism</measure>
    <time_frame>2 years post-transplant</time_frame>
    <description>Donor chimerism is determined by PCR analysis after cell separation into lymphoid and myeloid lineage cells using antibodies. Can also be detected by FISH analysis in the event of donor and recipient sex discrepancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution by laboratory evaluations</measure>
    <time_frame>1 year post-transplant</time_frame>
    <description>Immune reconstitution detected by absolute numbers of T cell phenotypes, B cells and NK cells. T cell function determined by proliferative response to mitogens. B cell function determined by evaluating anti-tetanus antibody titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall and disease free survival</measure>
    <time_frame>2 years post-transplant</time_frame>
    <description>Overall survival is defined as survival with or without disease Event free survival is defined as disease free, severe GVHD free survival, monitoring quality of life and relevant parameters.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Metabolic Disorders</condition>
  <condition>Hematologic, Immune, or Bone Marrow Disorders</condition>
  <condition>Hemoglobinopathies</condition>
  <condition>Non-malignant Disorders</condition>
  <arm_group>
    <arm_group_label>Stratum 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recipients with non-malignant disorders, excluding thalassemia. Related or unrelated 8/8 HLA-matched bone marrow</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recipient with transfusion dependent thalassemia. Related or unrelated. 8/8 HLA-matched bone marrow or 5-8/8 HLA-matched UCB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recipient with hemoglobinopathy Related or unrelated. 7/8 HLA-matched bone marrow or 5-8/8 HLA-matched UCB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recipient with non-malignant disorder, excluding hemoglobinopathy Related or unrelated. 7/8 HLA-matched bone marrow or 5-8/8 HLA-matched UCB</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment Plan 1: Stratum 1</intervention_name>
    <description>Day -50 to -21: Hydroxyurea 30mg/kg PO q day Day -22: Campath-1H 3 mg IV or SQ... Day -21: Campath-1H 10 mg IV or SQ... Day -20: Campath-1H 15 mg IV or SQ... Day -19: Campath-1H 20 mg IV or SQ... Day -8: Fludarabine 30mg/m2 IV... Day -7: Fludarabine 30mg/m2 IV... Day -6: Fludarabine 30mg/m2 IV... Day -5: Fludarabine 30mg/m2 IV... Day -4: Fludarabine 30mg/m2 IV... Day -3: Melphalan 140 mg/m2 IV... (dose modifications for patients &lt;10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on Day 0...</description>
    <arm_group_label>Stratum 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment Plan 2: Strata 2, 3, or 4</intervention_name>
    <description>Day -50 to -21: Hydroxyurea 30mg/kg PO q day… Day -22: Campath-1H 3 mg IV or SQ... Day -21: Campath-1H 10 mg IV or SQ... Day -20: Campath-1H 15 mg IV or SQ... Day -19: Campath-1H 20 mg IV or SQ... Day -8: Fludarabine 30mg/m2 IV... Day -7: Fludarabine 30mg/m2 IV... Day -6: Fludarabine 30mg/m2 IV... Day -5: Fludarabine 30mg/m2 IV... Day -4: Fludarabine 30mg/m2 IV... Day -4: Thiotepa 8mg/kg IV… Day -3: Melphalan 140 mg/m2 IV... (dose modifications for patients &lt;10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on day 0...</description>
    <arm_group_label>Stratum 2</arm_group_label>
    <arm_group_label>Stratum 3</arm_group_label>
    <arm_group_label>Stratum 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GVHD Regimen A: UCB Recipients</intervention_name>
    <description>Day -3: Begin Tacrolimus or cyclosporine Begin MMF Day -1: Abatacept 10mg/kg IV Day +5: Abatacept 10mg/kg IV Day +14: Abatacept 10mg/kg IV Day +28: Abatacept 10mg/kg IV Day +60: Abatacept 10mg/kg IV Day +100: Abatacept 10mg/kg IV</description>
    <arm_group_label>Stratum 2</arm_group_label>
    <arm_group_label>Stratum 3</arm_group_label>
    <arm_group_label>Stratum 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GVHD Regimen B: BM Recipients</intervention_name>
    <description>Day -3: Begin Tacrolimus or cyclosporine Begin MMF Day -1: Abatacept 10mg/kg IV Day +1: Methotrexate 7.5mg/m2 IV Day +3: Methotrexate 7.5mg/m2 IV Day +5: Abatacept 10mg/kg IV Day +6: Methotrexate 7.5mg/m2 IV Day +14: Abatacept 10mg/kg IV Day +28: Abatacept 10mg/kg IV Day +60: Abatacept 10mg/kg IV Day +100: Abatacept 10mg/kg IV Day +180: Abatacept 10mg/kg IV Day +270: Abatacept 10mg/kg IV Day +365: Abatacept 10mg/kg IV</description>
    <arm_group_label>Stratum 1</arm_group_label>
    <arm_group_label>Stratum 2</arm_group_label>
    <arm_group_label>Stratum 3</arm_group_label>
    <arm_group_label>Stratum 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Stratum 1: Patient must have non-malignant disorder, excluding thalassemia. Must be
        receiving a 8/8 HLA-matched bone marrow, related or unrelated Stratum 2: Patient must have
        thalassemia receiving 8/8 HLA-matched bone marrow or 5-8/8 HLA-matched UCB. Related or
        unrelated.

        Stratum 3: Patient must have a hemoglobinopathy receiving 7/8 HLA-matched bone marrow or
        5-8/8 HLA-matched UCB. Related or unrelated.

        Stratum 4: Patient must have a non-malignant disorder (excluding hemoglobinopathy)
        receiving 7/8 HLA-matched bone marrow or 5-8/8 HLA-matched UCB. Related or unrelated.

        All strata:

          -  Recipient age &lt; 21 years

          -  Lansky/Karnofsky &gt;/= 40

          -  Adequate pulmonary, renal, liver, and other organ function as defined in protocol

          -  Negative pregnancy test

          -  Adequate total nucleated cell or CD34+ dose of product as defined in protocol

          -  If sickle cell, Hemoglobin S &lt;30%

        Exclusion Criteria:

          -  HIV positive

          -  Invasive infection

          -  Pregnancy/lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shalini Shenoy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine (in St. Louis)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Murray, MA, CCRP</last_name>
    <phone>3144544240</phone>
    <email>murraylm@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Roberta Adams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Buchbinder, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Buchbinder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eric Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niketa Shah, MD</last_name>
    </contact>
    <investigator>
      <last_name>Niketa Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>George Washington University School of Medicine</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Jacobsohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin Andreansky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kamar Godder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gregory Hale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sonali Chaudhury, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Scott Goebel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisiana State University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lolie Yu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospitals and Clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mohamed Radhi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deepika Bhatla, MD</last_name>
    </contact>
    <investigator>
      <last_name>Deepika Bhatla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine (in St. Louis)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shalini Shenoy, MD</last_name>
      <phone>314-454-6018</phone>
      <email>shalinishenoy@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Murray, MA, CCRP</last_name>
      <phone>3144544240</phone>
      <email>murraylm@wustl.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alfred Gillio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Bhatia, MD</last_name>
    </contact>
    <investigator>
      <last_name>Monica Bhatia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Kent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Crawford, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Crawford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Troy Quigg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Guilcher, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gregory Guilcher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bhatla D, Davies SM, Shenoy S, Harris RE, Crockett M, Shoultz L, Smolarek T, Bleesing J, Hansen M, Jodele S, Jordan M, Filipovich AH, Mehta PA. Reduced-intensity conditioning is effective and safe for transplantation of patients with Shwachman-Diamond syndrome. Bone Marrow Transplant. 2008 Aug;42(3):159-65. doi: 10.1038/bmt.2008.151. Epub 2008 May 26.</citation>
    <PMID>18500373</PMID>
  </results_reference>
  <results_reference>
    <citation>Hansen MD, Filipovich AH, Davies SM, Mehta P, Bleesing J, Jodele S, Hayashi R, Barnes Y, Shenoy S. Allogeneic hematopoietic cell transplantation (HCT) in Hurler's syndrome using a reduced intensity preparative regimen. Bone Marrow Transplant. 2008 Feb;41(4):349-53. Epub 2007 Nov 19.</citation>
    <PMID>18026148</PMID>
  </results_reference>
  <results_reference>
    <citation>Rao A, Kamani N, Filipovich A, Lee SM, Davies SM, Dalal J, Shenoy S. Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. Blood. 2007 Jan 1;109(1):383-5. Epub 2006 Sep 21.</citation>
    <PMID>16990602</PMID>
  </results_reference>
  <results_reference>
    <citation>Shenoy S, Grossman WJ, DiPersio J, Yu LC, Wilson D, Barnes YJ, Mohanakumar T, Rao A, Hayashi RJ. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant. 2005 Feb;35(4):345-52.</citation>
    <PMID>15592491</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 15, 2009</study_first_submitted>
  <study_first_submitted_qc>June 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2009</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone marrow</keyword>
  <keyword>Transplant</keyword>
  <keyword>Transplantation</keyword>
  <keyword>Hematopoietic</keyword>
  <keyword>Umbilical cord</keyword>
  <keyword>Related</keyword>
  <keyword>Unrelated</keyword>
  <keyword>Reduced</keyword>
  <keyword>Non-myeloablative</keyword>
  <keyword>Nonmyeloablative</keyword>
  <keyword>Non-malignant</keyword>
  <keyword>Nonmalignant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinopathies</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

